GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » EV-to-FCF

Zealand Pharma A/S (Zealand Pharma A/S) EV-to-FCF : -75.05 (As of May. 21, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Zealand Pharma A/S's Enterprise Value is $5,208.74 Mil. Zealand Pharma A/S's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-69.41 Mil. Therefore, Zealand Pharma A/S's EV-to-FCF for today is -75.05.

The historical rank and industry rank for Zealand Pharma A/S's EV-to-FCF or its related term are showing as below:

ZLDPF' s EV-to-FCF Range Over the Past 10 Years
Min: -92.29   Med: -11.46   Max: 80.57
Current: -74.68

During the past 13 years, the highest EV-to-FCF of Zealand Pharma A/S was 80.57. The lowest was -92.29. And the median was -11.46.

ZLDPF's EV-to-FCF is ranked worse than
100% of 379 companies
in the Biotechnology industry
Industry Median: 8.34 vs ZLDPF: -74.68

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-21), Zealand Pharma A/S's stock price is $90.70. Zealand Pharma A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.838. Therefore, Zealand Pharma A/S's PE Ratio for today is At Loss.


Zealand Pharma A/S EV-to-FCF Historical Data

The historical data trend for Zealand Pharma A/S's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S EV-to-FCF Chart

Zealand Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.72 -10.72 -4.56 -10.10 -45.11

Zealand Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.79 -16.22 -21.04 -45.11 -85.28

Competitive Comparison of Zealand Pharma A/S's EV-to-FCF

For the Biotechnology subindustry, Zealand Pharma A/S's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's EV-to-FCF falls into.



Zealand Pharma A/S EV-to-FCF Calculation

Zealand Pharma A/S's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=5208.740/-69.405
=-75.05

Zealand Pharma A/S's current Enterprise Value is $5,208.74 Mil.
Zealand Pharma A/S's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-69.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zealand Pharma A/S  (OTCPK:ZLDPF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Zealand Pharma A/S's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=90.70/-1.838
=At Loss

Zealand Pharma A/S's share price for today is $90.70.
Zealand Pharma A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.838.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Zealand Pharma A/S EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma A/S (Zealand Pharma A/S) Headlines